FDAsafety guidance66% confidence
ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Sciegen Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Diabetes · SGLT2 Inhibitor
- Sub-indication
- General
Related signal: FDA Submission for Dapagliflozin by Sciegen Pharmaceuticals